Readystate Asset Management’s NewAmsterdam Pharma NAMS Stock Holding History

Readystate Asset Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-34,353	Closed	-$977K	–	441
2025 Q3	$977K	Sell	34,353 -196,841	-85%	-$4.72M	0.04%	200
2025 Q2	$4.19M	Buy	231,194 +1,532	+0.7%	+$27.9K	0.13%	114
2025 Q1	$4.7M	Sell	229,662 -30,738	-12%	-$683K	0.16%	105
2024 Q4	$6.69M	Buy	260,400 +139,400	+115%	+$2.96M	0.21%	106
2024 Q3	$2.01M	Buy	+121,000	New	+$2.09M	0.04%	363

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Readystate Asset Management's NAMS Position: Q4 2025 in Review

Readystate Asset Management sold out of NewAmsterdam Pharma (NAMS) in Q4 2025, closing a stake of 34,353 shares — an estimated $977K sold.

Readystate Asset Management first reported a position in NAMS in Q3 2024 and held it in 5 quarters. The position peaked at $6.69M in Q4 2024. 186 funds tracked by Wall St. Rank hold NAMS as of Q4 2025.

Readystate Asset Management reported no remaining NewAmsterdam Pharma position as of Q4 2025 after selling out during the quarter.
Readystate Asset Management sold 34,353 NewAmsterdam Pharma shares in Q4 2025, an estimated $977K.
Readystate Asset Management first reported a position in NewAmsterdam Pharma in Q3 2024 and held it in 5 quarters.
Readystate Asset Management's NewAmsterdam Pharma position peaked at $6.69M in Q4 2024.
186 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.